Alexander Schuth Net Worth

The estimated Net Worth of Alexander O. Schuth is at least $23.5 Million dollars as of 20 August 2024. Alexander Schuth owns over 8,353 units of Denali Therapeutics Inc stock worth over $4,822,027 and over the last 7 years he sold DNLI stock worth over $16,183,886. In addition, he makes $2,476,630 as Co-Founder, Chief Operating Officer und Secretary at Denali Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alexander Schuth DNLI stock SEC Form 4 insiders trading

Alexander has made over 56 trades of the Denali Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 8,353 units of DNLI stock worth $200,388 on 20 August 2024.

The largest trade he's ever made was selling 70,000 units of Denali Therapeutics Inc stock on 4 January 2021 worth over $5,246,500. On average, Alexander trades about 8,479 units every 35 days since 2018. As of 20 August 2024 he still owns at least 178,066 units of Denali Therapeutics Inc stock.

You can see the complete history of Alexander Schuth stock trades at the bottom of the page.

Alexander Schuth biography

Dr. Alexander O. Schuth M.D. serves as Co-Founder, Chief Operating Officer, Secretary of the Company. Dr. Schuth co-founded and joined Denali from Genentech, where he held various roles of increasing responsibility between 2005 and 2015; from September 2014 to March 2015, Dr. Schuth served as Head of Technology Innovation and Diagnostics Partnering; from March 2010 to September 2014, Dr. Schuth served as Head of Neuroscience Partnering; from January 2007 to March 2010, Dr. Schuth worked in the business development team; and from August 2005 to January 2007, Dr. Schuth worked as an R&D finance manager. From January 2001 to May 2003, he served as Investment Banking Associate in the equity capital markets group at Merrill Lynch in London. He currently serves on the board of directors of Molecular Health, a privately held biopharmaceutical company. Dr. Schuth received his M.B.A. from The Wharton School of the University of Pennsylvania and his M.D. from the Charite Medical School at the Humboldt University in Berlin, Germany.

What is the salary of Alexander Schuth?

As the Co-Founder, Chief Operating Officer und Secretary of Denali Therapeutics Inc, the total compensation of Alexander Schuth at Denali Therapeutics Inc is $2,476,630. There are 3 executives at Denali Therapeutics Inc getting paid more, with Ryan Watts having the highest compensation of $4,978,610.

How old is Alexander Schuth?

Alexander Schuth is 46, he's been the Co-Founder, Chief Operating Officer und Secretary of Denali Therapeutics Inc since 2015. There are 16 older and 3 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.

What's Alexander Schuth's mailing address?

Alexander's mailing address filed with the SEC is 151 Oyster Point Blvd, South San Francisco, CA 94080, USA.

Insiders trading at Denali Therapeutics Inc

Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin... und Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.

What does Denali Therapeutics Inc do?

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Complete history of Alexander Schuth stock trades at Denali Therapeutics Inc

Denali Therapeutics Inc executives and stock owners

Denali Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ryan Watts,
  President, Chief Executive Officer, Co-Founder, Director
• Steve Krognes,
  Chief Financial Officer, Treasurer
• Carole Ho,
  Chief Medical Officer, Head of Development
• Alexander Schuth,
  Co-Founder, Chief Operating Officer, Secretary
• Dr. Ryan J. Watts Ph.D.,
  Co-Founder, Pres, CEO & Director
• Steve Edward Krognes,
  CFO & Treasurer
• Dr. Carole Ho,
  Chief Medical Officer & Head of Devel.
• Dr. Alexander O. Schuth M.D.,
  Co-Founder, COO & Sec.
• Dr. Carole Ho M.D.,
  Chief Medical Officer & Head of Devel.
• Vicki Sato,
  Independent Chairman of the Board
• Marc Tessier-Lavignec,
  Independent Director
• Peter Klein,
  Independent Director
• David Schenkein,
  Independent Director
• Jay Flatley,
  Independent Director
• Douglas Cole,
  Independent Director
• Robert Nelsen,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Marc Tessier-Lavigne Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Dr. Marc Tessier-Lavigne,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Chris Walsh,
  Associate Gen. Counsel
• Dr. Laura Hansen,
  VP of Investor Relations
• Joe Lewcock,
  Chief Scientific Officer
• Dr. Dana Andersen,
  Chief Technical and Manufacturing Officer
• Tyler M. Nielsen,
  VP of Corp. Fin.
• Douglas Kakdl, L.P.Neuro Li...,
  
• Ventures Fund V, L.P.Afeyan...,
  
• Marc Tessier Lavigne,
  Director
• Ltd Fil,
  
• Llc Fmr,
  
• Venture Fund Viii, L.P.Arch...,
  
• Douglas K Neuro Line Partne...,
  
• Douglas Kakdl, L.P.Crestlin...,
  
• Nancy Thornberry,
  Director
• Erik Harris,
  Director